Naughty Flicks

Skip NavigationMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting ClubPROLivestreamMenuKura Oncology ‘s growing cancer drug sales and promising pipeline could fuel a rally in its stock, according to JPMorgan. Analyst Priyanka Grover initiated coverage with an overweight rating and a year-end price target of $30, implying 180% upside to Wednesday’s close of $10.71. Shares were trading up about 1% on Thursday. The bullish call centers on Kura’s transition into a commercial-stage company after Komzifti received Food and Drug Administration approval in November 2025 for adults with acute myeloid leukemia carrying a NPM1 mutation whose cancer has returned or failed to respond to treatment. Early sales of the once-daily pill point to “aggressive physician adoption,” Grover wrote. Since Komzifti’s commercial launch, net product revenue has increased from $2.1 million in the final five weeks of 2025 to $9.1 million in the second quarter of 2026. JPMorgan sees an opportunity to expand its use to newly diagnosed patients, estimating roughly $1.5 billion in potential worldwide peak sales across those markets. Kura has “clear potential” to capture meaningful share of the leukemia market, JPMorgan said. KURA YTD mountain Kura Oncology’s YTD performance. Grover’s sum-of-the-parts analysis also weighs the potential of its experimental cancer drug, darlifarnib, which is designed to block specific tumor growth signals. JPMorgan estimates the drug could have $600 million in potential worldwide peak sales. JPMorgan said darlifarnib provides the San Diego-based company with “a potential second oncology franchise.” In an April data study, Kura Oncology said a combination of darlifarnib and cabozantinib, another targeted therapy to treat advanced cancers, “demonstrated robust antitumor activity.” Kura shares have “significant upside potential,” JPMorgan said, as clinical trials progress and the market better appreciates opportunities from both treatments.Read More